Pharmacogenomics for clinical trials of COVID-19 medicines: Why is this important now?
Yükleniyor...
Dosyalar
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
OMICS
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Historically, pharmacogenomics has origins in biochemical genetics in the 20th century and astute observations on unusual clinical responses to medicines. Extreme drug response phenotypes observed in the clinic have triggered molecular research on mechanisms of personto-person variations in drug safety and efficacy (Kalow, 1962; Ozdemir et al., 2009), and paved the way for the contemporary field of pharmacogenomics.
Açıklama
Anahtar Kelimeler
Kaynak
Journal of Integrative Biology
WoS Q Değeri
Q2
Scopus Q Değeri
N/A
Cilt
25
Sayı
11
Künye
Şardaş, S., & Özdemir, V. (2021). Pharmacogenomics for Clinical Trials of COVID-19 Medicines: Why Is This Important Now?. Omics : a journal of integrative biology, 10.1089/omi.2021.0176. Advance online publication. https://doi.org/10.1089/omi.2021.0176
